Alzamend Neuro, Inc. ALZN
We take great care to ensure that the data presented and summarized in this overview for Alzamend Neuro, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ALZN
Top Purchases
Top Sells
About ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
Insider Transactions at ALZN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 06
2024
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
75
+0.1%
|
$150
$2.75 P/Share
|
|
Jul 31
2024
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
25
+0.03%
|
$75
$3.74 P/Share
|
|
Apr 19
2024
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.13%
|
$0
$0.69 P/Share
|
|
Apr 01
2024
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
334
+0.04%
|
$0
$0.91 P/Share
|
|
Jan 23
2024
|
Milton C Ault Iii |
SELL
Other acquisition or disposition
|
Indirect |
661,168
-99.18%
|
-
|
|
Jan 05
2024
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
7,000
+0.45%
|
$7,000
$1.04 P/Share
|
|
Dec 26
2023
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
500
+1.88%
|
$0
$0.9 P/Share
|
|
Dec 22
2023
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Direct |
200
+0.12%
|
$0
$0.92 P/Share
|
|
Sep 26
2023
|
David J Katzoff Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
53,000
+39.55%
|
$0
$0.19 P/Share
|
|
May 24
2023
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
18,000
+4.49%
|
$0
$0.59 P/Share
|
|
Apr 28
2023
|
Stephan Jackman Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
37,000
+44.85%
|
$0
$0.54 P/Share
|
|
Mar 22
2023
|
Lynne Fahey Mc Grath |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$0
$0.44 P/Share
|
|
Mar 17
2023
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.05%
|
$0
$0.43 P/Share
|
|
Mar 16
2023
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
4,000
+0.04%
|
$0
$0.5 P/Share
|
|
Feb 24
2023
|
William B. Horne |
BUY
Exercise of conversion of derivative security
|
Direct |
500,000
+33.33%
|
-
|
|
Feb 15
2023
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.01%
|
$0
$0.6 P/Share
|
|
Dec 28
2022
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
3,100
+0.03%
|
$0
$0.56 P/Share
|
|
Dec 27
2022
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
900
+0.01%
|
$0
$0.59 P/Share
|
|
Dec 21
2022
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.05%
|
$0
$0.81 P/Share
|
|
Dec 19
2022
|
Milton C Ault Iii |
BUY
Open market or private purchase
|
Indirect |
23,000
+2.61%
|
$0
$0.82 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 1.43K shares |
|---|
| Other acquisition or disposition | 661K shares |
|---|